8,560
Total Claims
$2.5M
Drug Cost
827
Beneficiaries
$3,039
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+99%
Cost per patient vs peers
$3,039 vs $1,524 avg
+80%
Brand preference vs peers
24.5% vs 13.7% avg
Brand vs Generic
76% generic
Brand: 2,100 claims · $2.3M
Generic: 6,460 claims · $186K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 463 | $551K |
| Rivaroxaban | 295 | $380K |
| Empagliflozin | 252 | $307K |
| Sacubitril/Valsartan | 191 | $246K |
| Evolocumab | 172 | $178K |
| Alirocumab | 169 | $169K |
| Dapagliflozin Propanediol | 133 | $147K |
| Ticagrelor | 139 | $83K |
| Dronedarone Hcl | 41 | $63K |
| Icosapent Ethyl | 63 | $55K |
| Semaglutide | 20 | $40K |
| Vericiguat | 25 | $34K |
| Bempedoic Acid/Ezetimibe | 26 | $22K |
| Ezetimibe | 449 | $17K |
| Icosapent Ethyl | 24 | $15K |
Prescribing Profile
Patient Profile
78
Avg Age
38%
Female
1.25
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data